|ATC code||C01AA09 (WHO)|
|Chemical and physical data|
|Molar mass||920.989 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Gitoformate (INN, or pentaformylgitoxin, trade name Dynocard) is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). Produced by Madaus, it is not available in the US, and does not seem to be available in Europe either.
Gitoformate is a derivative of the glycoside gitoxin, with five of the six free hydroxyl groups formylated, one on the aglycon and four on the sugar. Gitoxin, a cardiac glycoside from the woolly foxglove (Digitalis lanata), has an aglycon of the cardenolide type named gitoxigenin, which is also the aglycon of lanatoside B, another Digitalis lanata glycoside.
- Rietbrock, N.; Woodcock, B. G.; Hrazdil, U. (1984). "Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency". Arzneimittel-Forschung. 34 (8): 915–917. PMID 6541927.
- Dei Cas, L.; Affatato, A.; Buia, E.; Casciarri, G.; Faggiano, P.; Giunti, G.; Metra, M.; Pelagatti, T.; Quinzanini, M. (1984). "Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate". Cardiologia (Rome, Italy). 29 (5–6): 291–300. PMID 6542412.
- CID 91540 from PubChem
- William O. Foye,Thomas L. Lemke, David A. Williams. Foye's principles of medicinal chemistry. p. 699. ISBN 978-0-7817-6879-5.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|